The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Sequential administration of new agents (NAs) after docetaxel (DOC) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts): Impact of disease control (DC) duration in second line on the subsequent line outcomes.
 
Francesca Maines
No Relationships to Disclose
 
Ugo De Giorgi
No Relationships to Disclose
 
Gaetano Facchini
No Relationships to Disclose
 
Lucia Fratino
No Relationships to Disclose
 
Donatello Gasparro
No Relationships to Disclose
 
Daniele Alesini
No Relationships to Disclose
 
Umberto Basso
No Relationships to Disclose
 
Marcello Tucci
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen
 
Cinzia Ortega
Consulting or Advisory Role - Astellas Pharma
 
Sarah Scagliarini
No Relationships to Disclose
 
Francesco Verderame
No Relationships to Disclose
 
Sandro Barni
No Relationships to Disclose
 
Alessandro D'Angelo
No Relationships to Disclose
 
Giovanni Vicario
No Relationships to Disclose
 
Maddalena Donini
No Relationships to Disclose
 
Francesco Carrozza
No Relationships to Disclose
 
Teodoro Sava
No Relationships to Disclose
 
Zuzana Sirotova
No Relationships to Disclose
 
Daniele Santini
No Relationships to Disclose
 
Orazio Caffo
Honoraria - Astellas Pharma; Janssen Oncology; Sanofi